June 14 - Therapy-Specific Considerations II

The first presentation, Therapy Specific Considerations for RAI, will review the therapy-specific considerations for RAI toward the treatment of thyroid cancer. Discussion will include the basic mechanism, indications and toxicities of RAI therapy.

Hepatic brachytherapy using intra-arterial Y90 microspheres is a maturing therapy that often is delivered without the concomitant application of personalized dosimetry planning and post-treatment confirmatory dosimetry, multidisciplinary consultation, and collaborative management prior to and post liver-directed RPT.  The second presentation, Therapy-Specific Considerations for Liver-Directed RPT/SIRT, will review the eligibility criteria for liver-directed radiotherapy using Y90 and the estimated absorbed does in tumor and normal live prior to and after implementation.

Topics:

  • Therapy-Specific Considerations for RAI - Stephanie S. Markovina, MD, PhD, and Nikhil Rammohan, MD, PhD
  • Therapy-Specific Considerations for Liver-Directed Radiopharmaceutical Therapy / Selective Internal Radiation Therapy - Andrew Kennedy, MD

Target Audience

This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation dosimetrists, radiation therapists, medical oncologists, surgeons, interventional radiologists and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Describe the basic mechanism of RAI therapy.
  • Discuss the indications for RAI therapy in thyroid cancer.
  • Explain the toxicities of RAI therapy.
  • Explain the eligibility criteria for a patient to be considered for liver-directed radiotherapy using Y90 (SIRT).
  • Determine the estimated absorbed dose of Y90 in tumor and normal liver prior to, and after implantation of Y90 in the liver for unresectable solid tumors.
  • Analyze the patient for Y90 treatment who has previously received hepatic external beam radiotherapy.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.
Course opens: 
03/28/2024
Course expires: 
07/04/2026
Cost:
$0.00
Rating: 
0
  • Stephanie S. Markovina, MD, PhD, is employed by Washington University School of Medicine in St. Louis. Dr. Markovina receives travel expenses from NCCN. Dr. Markovina is the PI on research grants with the National Cancer Institute/NIH and Tesaro, Inc. 
  • Nikhil Rammohan, MD, PhD, is employed by Washington University School of Medicine in St. Louis. 
  • Andrew Kennedy, MD, is employed by the Sarah Cannon Cancer Center at TriStar Health. Dr. Kennedy receives compensation from ABK Medical and Bard.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.